Thiogenesis Therapeutics Corp (TTI.CA) Fundamental Analysis & Valuation

TSX-V:TTI

Current stock price

0.495 CAD
-0.01 (-1%)
Last:

This TTI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. TTI.CA Profitability Analysis

1.1 Basic Checks

  • In the past year TTI has reported negative net income.
  • In the past year TTI has reported a negative cash flow from operations.
TTI.CA Yearly Net Income VS EBIT VS OCF VS FCFTTI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -1M -2M -3M -4M -5M

1.2 Ratios

Industry RankSector Rank
ROA -188.16%
ROE -316.78%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TTI.CA Yearly ROA, ROE, ROICTTI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • TTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TTI.CA Yearly Profit, Operating, Gross MarginsTTI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. TTI.CA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, TTI has more shares outstanding
  • TTI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TTI.CA Yearly Shares OutstandingTTI.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10B 20B 30B
TTI.CA Yearly Total Debt VS Total AssetsTTI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • Based on the Altman-Z score of -2.01, we must say that TTI is in the distress zone and has some risk of bankruptcy.
  • There is no outstanding debt for TTI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.01
ROIC/WACCN/A
WACCN/A
TTI.CA Yearly LT Debt VS Equity VS FCFTTI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • TTI has a Current Ratio of 2.46. This indicates that TTI is financially healthy and has no problem in meeting its short term obligations.
  • TTI has a Quick Ratio of 2.46. This indicates that TTI is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 2.46
TTI.CA Yearly Current Assets VS Current LiabilitesTTI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. TTI.CA Growth Analysis

3.1 Past

  • TTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49.12%.
EPS 1Y (TTM)-49.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-230.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • TTI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 187.57% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.12%
EPS Next 2Y167.96%
EPS Next 3Y173.22%
EPS Next 5Y187.57%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TTI.CA Yearly Revenue VS EstimatesTTI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B
TTI.CA Yearly EPS VS EstimatesTTI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 0 10 20 30 40 50

More info and screens

Find the best growth stocksShow best growing peers

2

4. TTI.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • TTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 0.83, which indicates a rather cheap valuation of TTI.
  • TTI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.84.
Industry RankSector Rank
PE N/A
Fwd PE 0.83
TTI.CA Price Earnings VS Forward Price EarningsTTI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TTI.CA Per share dataTTI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4

4.3 Compensation for Growth

  • TTI's earnings are expected to grow with 173.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y167.96%
EPS Next 3Y173.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TTI.CA Dividend Analysis

5.1 Amount

  • TTI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TTI.CA Fundamentals: All Metrics, Ratios and Statistics

Thiogenesis Therapeutics Corp

TSX-V:TTI (3/12/2026, 7:00:00 PM)

0.495

-0.01 (-1%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-25
Earnings (Next)04-23
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners16.9%
Ins Owner ChangeN/A
Market Cap25.66M
Revenue(TTM)N/A
Net Income(TTM)-6.82M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.83
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.92
P/tB 11.92
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)0.6
Fwd EY120.62%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -188.16%
ROE -316.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.46
Quick Ratio 2.46
Altman-Z -2.01
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-230.56%
EPS Next Y-9.12%
EPS Next 2Y167.96%
EPS Next 3Y173.22%
EPS Next 5Y187.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-59.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0%
EBIT Next 3Y169.14%
EBIT Next 5Y184.63%
FCF growth 1Y-20.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.69%
OCF growth 3YN/A
OCF growth 5YN/A

Thiogenesis Therapeutics Corp / TTI.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Thiogenesis Therapeutics Corp?

ChartMill assigns a fundamental rating of 2 / 10 to TTI.CA.


Can you provide the valuation status for Thiogenesis Therapeutics Corp?

ChartMill assigns a valuation rating of 2 / 10 to Thiogenesis Therapeutics Corp (TTI.CA). This can be considered as Overvalued.


How profitable is Thiogenesis Therapeutics Corp (TTI.CA) stock?

Thiogenesis Therapeutics Corp (TTI.CA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for Thiogenesis Therapeutics Corp?

The Earnings per Share (EPS) of Thiogenesis Therapeutics Corp (TTI.CA) is expected to decline by -9.12% in the next year.